Comparative Evaluation of Typical Vs Atypical antipsychotics in the treatment of stable Schizophrenia
Not Applicable
Completed
- Conditions
- Health Condition 1: F209- Schizophrenia, unspecifiedHealth Condition 2: null- Stable Schizophrenic patients
- Registration Number
- CTRI/2020/01/022712
- Lead Sponsor
- Dr Subhash Vishal
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 98
Inclusion Criteria
Stable schizophrenic with initial BPRS score of >= 24, Clinical Global Impression Severity Rating Scale >= 4
Exclusion Criteria
Age less than 18 or more than 70; pregnant or lactating women, acute emergencies, patients with impaired hepatic or renal function; any systemic illness; history of hypersensitivity / allergy to any of the drugs included in study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method All of three atypical antipsychotics olanzapine, aripiprazole and risperidone were found to be more effective as well as safer in terms of changes in BPRS, PAN-SS, CGI and CDRS scores as compared to typical antipsychotic haloperidol.Timepoint: 01.01.2015 - 31.12.2015
- Secondary Outcome Measures
Name Time Method o secondary outcome(s)Timepoint: Not applicable